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Abstract
Background and objective
The presence of executive deficits in patients with Amyotrophic Lateral Sclerosis is well
established, even if standardized measures are difficult to obtain due to progressive physi-
cal disability of the patients. We present clinical data concerning a newly developed mea-
sure of cognitive flexibility, administered by means of Eye-Tracking (ET) technology in order
to bypass verbal-motor limitations.
Methods
21 ALS patients and 21 age-and education-matched healthy subjects participated in an ET-
based cognitive assessment, including a newly developed test of cognitive flexibility (Arrows
and Colors Cognitive Test–ACCT) and other oculomotor-driven measures of cognitive func-
tions. A standard screening of frontal and working memory abilities and global cognitive effi-
ciency was administered to all subjects, in addition to a psychological self-rated
assessment. For ALS patients, a clinical examination was also performed.
Results
ACCT successfully discriminated between patients and healthy controls, mainly concerning
execution times obtained at different subtests. A qualitative analysis performed on error dis-
tributions in patients highlighted a lower prevalence of perseverative errors, with respect to
other type of errors. Correlations between ACCT and other ET-based frontal-executive
measures were significant and involved different frontal sub-domains. Limited correlations
were observed between ACCT and standard ‘paper and pencil’ cognitive tests.
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Conclusions
The newly developed ET-based measure of cognitive flexibility could be a useful tool to
detect slight frontal impairments in non-demented ALS patients by bypassing verbal-motor
limitations through the oculomotor-driven administration. The findings reported in the pres-
ent study represent the first contribution towards the development of a full verbal-motor free
executive test for ALS patients.
Introduction
Cognitive and behavioral changes in patients with Amyotrophic Lateral Sclerosis (ALS) are
now recognized as integral features of the disease [1]. Despite recent findings showing the
presence of heterogeneous cognitive profiles in ALS [2–4], the most commonly reported alter-
ations involve executive functions, with literature consistently highlighting behavioral, neuro-
physiological, and cognitive correlates of frontal alterations in such populations [5,6]. The
most consistent impairments have been observed on tests of phonemic verbal fluency [7] and
remain evident even after the results were adjusted for verbal and motor impairment [8]. Ver-
bal fluency execution involves processes of set-shifting, inhibition, sustained attention, and
working memory [9]. A recent study highlighted that set-shifting and initiation are the most
common executive sub-functions that are impaired in non-demented ALS patients; con-
versely, inhibition and problem-solving abilities seem less affected in this population [10].
Another study, involving meta-analysis, confirmed that set-shifting assessment performed by
means of Wisconsin Card Sorting Test (WCST) [11] allows to detect a typical and selective
component of executive functions impairment in ALS [12]. Other tests to assess global cogni-
tive [Montreal Cognitive Assessment (MoCA)] and executive function [Frontal Assessment
Battery (FAB) and Edinburgh Cognitive and Behavioural ALS Screen (ECAS)] failed to distin-
guish between patients and healthy controls.
In addition to set shifting abilities, cognitive flexibility is impaired in ALS patients due to
limitations in executive control [13]. However, such observations have been collected by
means of tests that did not accommodate for verbal and motor disability of ALS patients; such
issues may at least partially account for the inconsistency of findings obtained by previous
studies [14].
Executive dysfunction in ALS is recognized as a relevant factor that influences disease man-
agement and progression [15–17]. Moreover, longitudinal assessment of such abilities is help-
ful to clarify clinical phenotypes, according to biological and behavioral characteristics, and
define prognosis. For these reasons, the development of validated motor-verbal free measures
to assess cognitive functions, and in particular frontal-executive abilities, could improve both
the phenotype description and care of patients [13].
Recently, some attempts have been made in order to obtain verbal-motor free indicators of
changes in executive function of patients with ALS. In particular, event-related potentials
(ERP) have been employed to assess frontal involvement with minimal motor demands [12,
14, 18–19]. ERP measurements require complex, expensive equipment and specific competen-
cies in order to detect and analyze subtle changes in frontal cognitive activity in ALS patients
without dementia. Moreover, the quantitative and qualitative data derived from ERP measure-
ments are not comparable with scores obtained from standard cognitive testing. Therefore,
these measures cannot be used for a longitudinal evaluation of neuropsychological functions.
Recent studies have also used untimed measures that did not depend on a specific response
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modality, allowing patients to respond verbally or manually [20–22]. However, even the pres-
ence of minimal motor functions could be prevented in the advanced stages of the disease.
Eye Tracking (ET), a well-known and consistently validated Alternative and Augmentative
Communication system, has been used with the aim of administering neuropsychological tests
in a motor-verbal free manner [23–26]. We recently presented preliminary results showing an
extensive neuropsychological battery developed for ET control, covering language, attentional
and executive functions, and social cognition domains [27–29]. The current study describes
clinical data on a newly developed measure of cognitive flexibility, the Arrows and Colors Cog-
nitive Test (ACCT), administered by means of ET technology. Relationships between other
validated standard measures and with the recently proposed oculomotor-driven neuropsycho-
logical battery are discussed, together with sensitivity in discriminating between ALS patients
and healthy controls.
Materials and methods
Participants
Twenty-one ALS patients were recruited at the inpatient-outpatient ALS Center at the Depart-
ment of Neurology of the IRCCS Istituto Auxologico Italiano, Milan. The diagnosis of definite
ALS was made by an expert consultant neurologist, according to El Escorial Criteria [30].
Patients were excluded if they were in terminal stages of disease or had major medical, neuro-
logical, psychiatric history, and/or cardiovascular comorbidities. None of the patients had
major visual impairments or oculomotor dysfunction. Twenty-one healthy subjects, matched
for age and educational levels, were also recruited. All participants were native Italian
speakers.
For ALS patients, clinical and laboratory assessments included evaluation of disability,
using the revised ALS Functional Rating Scale (ALSFRS/R) [31], and of respiratory function
with spirometry.
All participants completed the designed cognitive and psychological protocols and the ET-
based assessment, as described below.
The study protocol was reviewed and approved by the Ethics Committee of IRCCS Istituto
Auxologico Italiano (ethics committee code: 2011_04_12_16) and all eligible subjects received ver-
bal and written information about the study. All participants signed an informed consent, accord-
ing to the Declaration of Helsinki. The individual in this manuscript (S1 and S2 Videos) has given
written informed consent (as outlined in PLOS consent form) to publish these case details.
Cognitive and psychological assessment
ACCT: ET-based assessment of cognitive flexibility. ACCT is composed by four rows
(ACCT-1, ACCT-2, ACCT-3, ACCT-4), made of 12 items each, where participants are
required to select the appropriate arrow according to a written instruction. The patients were
allowed to practice each trial twice before the start of data collection. Two types of instructions
were presented. In the first (ACCT-1, see S1 Video; the individual in this manuscript has given
written informed consent, as outlined in PLOS consent form, to publish these case details) and
third (ACCT-3) trials: “Note the arrow in the upper center. In the following exercise, you will be
asked to choose between the arrows below, the one with the different color, but the same direction
as that of the target arrow”. In the second (ACCT-2) and fourth (ACCT-4, see S2 Video; the
individual in this manuscript has given written informed consent, as outlined in PLOS consent
form, to publish these case details) trials: “Note the arrow in the upper center. In the following
exercise, you will be asked to choose, between the arrows below, the one with the same color, but a
different direction from that of the target arrow”. Upper arrows are equally distributed between
Oculomotor-based executive assessment in ALS
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four directions (3 arrows for each direction). Target arrows are equally distributed between
the right, left and central positions (4 for each position in 3-arrow trials, 3 for each position in
4-arrow trials). For each task, two or three distracters were present for ACCT-1 and ACCT-2
and for ACCT-3 and ACCT-4 respectively; distracters were represented by items following a
part of the instruction (i.e. color or direction), and by a perseverative response over the previ-
ous subtest (see Fig 1). The mean latency, mean latency standard deviation, and the total num-
ber of correct responses were recorded for each subtest. Moreover, partial errors (i.e. following
Fig 1. Structure and instructions of the four ACCT subtests.
https://doi.org/10.1371/journal.pone.0200953.g001
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a part of the instructions) and perseverative errors were computed for each subtest, in order to
obtain additional qualitative data about subjects’ performances.
Other standard and ET-based cognitive and psychological tests. A neuropsychological
and psychological protocols employed in previous studies were adopted, including both stan-
dard and ET-based cognitive measures. In particular, standard cognitive measures included
two brief batteries, for dysexecutive syndrome, FAB [32], and global cognitive functioning,
MoCA [33], respectively, and a working memory—WM subtest, Digit Sequencing Task of the
Brief Assessment of Cognition in Schizophrenia (BACS) [34].
In addition, a battery of neuropsychological tests, previously adapted to oculomotor control
by means of ET technology, was employed for evaluating language (Token Test), attentional
abilities (d2 Test), executive functions (Raven’s Colored Progressive Matrices—RCPM, Modi-
fied Card Sorting Test–MCST, Iowa Gambling task–IGT) and social cognition (Reading the
Mind in the eyes test–RME) [28,29].
In addition, participants completed a screening for symptoms of depression and anxiety,
using both the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory-Y
(STAI-Y). BDI was used to assesses both cognitive-affective (BDI-CA) and somatic-perfor-
mance (BDI-SP) symptoms of depression [35], and STAI-Y evaluated both state anxiety level
(STAI-Y1) and trait anxiety (STAI-Y2) components [36]. For ALS patients, a behavioral
assessment was also performed using the Frontal Behavioral Inventory (FBI) [37].
Eye-Tracking
An EyeLink 1000 infrared tracker was used to record participants’ eye movements throughout all
the experimental conditions. Head position was stabilized using a chin rest, at a distance from the
screen of around 70 cm. A nine-points calibration covering the totality of the visual screen and a
drift correction were carried out before each test, in order to ensure an accurate eye position
recording. In order to select an item on the computer screen, participants were required to fixate
on the item for a minimum of 80% over a period of 1,500 milliseconds. Eye movement data con-
sisted of moment-to-moment measures of eyes’ displacements along the vertical and horizontal
axes (in millimeters) within the spatial working area of the monitor screen (resolution 1024 x 768
pixels). Pupil dilation and gazes were acquired, based on pupil position and corneal reflection on
the frontal surface of participants’ eyes (caused by an infrared light source), at 250 Hz by means of
an EyeLink 1000 system using a new software suite, named the eBrain Test Engine (ETE, http://
ebrainengine.codeplex.com/). Acquired signals were also analyzed using the following off-line
tools: Experiment Builder (SR Research, Ottawa, Canada), Excel (Microsoft, Redmond, USA) and
custom programs written in MATLAB 7.2 (The Mathworks, Inc.; Natick, MA). A training phase
was performed, as described in previous works [28,29].
Procedure
The overall experimental procedure was performed along two sessions within a one week
period. In the first session, standard cognitive tests and psychological measures were adminis-
tered. In addition, the subjects participated in a training phase for the ET evaluation. During
the second session, participants underwent the ET-based neuropsychological assessment. The
administration order of each ET neuropsychological test was randomized among subjects, in
order to avoid practice and fatigue effects.
Statistical analysis
Descriptive statistics (mean ± standard deviations for continuous variables and frequencies for
discrete variables) were used to describe the main characteristics of the recruited samples and
Oculomotor-based executive assessment in ALS
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performances of the ET and standard cognitive/psychological assessments. Distribution of the
variables in terms of proximity to normal curve and the homogeneity of variances were
detected by the Shapiro-Wilk test and Bartlett test, respectively. To compare the mean scores
between groups, a two-sided t-test with pooled estimates of the sample variance or the Welch
approximation were employed when the continuous variables were normally distributed,
homoscedastic or heteroscedastic, respectively. Otherwise, a two-sided signed-rank test was
performed. Finally, to assess the degree of association between scores in the ALS patients, the
Spearman correlation coefficient was adopted. P-values were adjusted with for a false discovery
rate.
To detect the sensitivity and the specificity of ET test, the area under the receiver operating
characteristic (ROC) curve (AUC) was evaluated; cut off values were identified according to
the Youden’s J statistic method [38]. An α level of 0.05 was used for all hypothesis tests. All
data analyses were performed using R Core Team (2014), Vienna, Austria.
Results
Healthy participants and patients’ demographic and clinical characteristics
Twenty-one ALS patients (males: 18; females: 3; age: 59.33 ± 11.84 years; education:
11.52 ± 3.39 years; disease duration: 33.62 ± 42.71 months) and 21 matched healthy partici-
pants (males: 9; females: 12; age: 57.38 ± 10.78 years; education: 12.52 ± 3.47) were recruited.
For the patients’ group, clinical neurological examination showed an ALSFRS/R score of
37.57 ± 6.05 (ALSFRS/R Bulbar: 9.67 ± 2.89). Ten ALS patients had upper limb regions at
onset, 8 had lower limb regions, 3 were bulbar, and no patient had respiratory symptoms at
onset. According to the recent Strong and colleagues’ classification of ALS-FTD spectrum dis-
order (Strong et al., 2017), four patients (22.22%) were classified as having ALS with behavioral
impairment (ALSbi) and two (12.5%) with cognitive impairment (ALSci). No patient was clas-
sified as having ALS which met the criteria for both ALSci and ALSbi (ALScbi), ALS with fron-
totemporal dementia (ALS-FTD) or ALS-dementia. At the standard neuropsychological
assessment, patients performed significantly worse than healthy participants at the MoCA
(ALS patients: 25.53 ± 2.43, controls: 27.14 ± 1.93, t = -2.28, p-value = .028), and the WM sub-
test (ALS patients: 20.19 ± 3.34, controls: 22.28 ± 2.34, Z = -2.22, p-value = .025), while no dif-
ferences were observed with FAB (ALS patients: 16.30 ± 1.06, controls: 16.50 ± 1.18, t = -0.54,
p-value = .60).
ACCT results: Between groups differences
The performances of patients and controls were different when assessed through ACCT, with
significantly higher values of mean latency observed for patients at ACCT-1, ACCT-2, and
ACCT-4 subtests. Significantly higher values of the mean latency standard deviation were
observed for patients for the ACCT-1 and ACCT-4 assessments, suggesting a larger variability
of performances in this group compared to the control group. A tendency towards a significant
difference in number of correct responses was observed for ACCT-4, with lower scores for
patients (Table 1). Significantly higher values of mean latency for only correct responses were
observed in ALS patients’ group, for ACCT-1, ACCT-2, and ACCT-4 subtests (S1 Table).
The ROC curve analysis supported the sensitivity of ACCT-1, ACCT-2, ACCT-4 mean
latency and mean latency standard deviation variables (AUC values >0.70), according to the
determined cut-off scores. AUC values between 0.6 and 0.7 were found for ACCT-3 number
of correct responses and for ACCT-3 mean latency.
A qualitative analysis on patients’ performances of the types of errors committed
highlighted an increasing number of perseverative errors during the ACCT-3 to ACCT-4
Oculomotor-based executive assessment in ALS
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subtests. However, perseverative errors were globally less present than partial ones, with a
prevalence of partial (color) errors in ACCT-1, ACCT-3 and ACCT-4 subtests. For ACCT-2, a
higher proportion of partial (direction) errors, with respect to partial (color) ones, was
observed (Fig 2).
ACCT results: Correlation with other standard and ET-based cognitive
tests
When considering the ALS group (Table 2), significant correlations were observed between
MoCA and ACCT-1 mean latency and number of correct responses; between FAB and
ACCT-3 number of correct responses. Correlations between ACCT and WM subtest only con-
cerned mean latency standard deviation of ACCT-2, even if a tendency toward a significant
correlation (p-value = .06) was observed for the mean latency standard deviation of ACCT-3,
and number of correct responses for ACCT-2. For controls (Table 2), significant correlations
were observed between MoCA and the number of correct responses of ACCT-3, with a mean
latency trend close to significant (p-value = .06) for ACCT-3; between WM subtest and the
mean latency standard deviation of ACCT-2, with a trend toward a significant correlation (p-
value = .06) for mean latency correlation of ACCT-2. Conversely, the FAB did not correlated
with any of the ACCT variables in controls’ groups.
When correlations between ACCT and other ET-based neuropsychological tests were con-
sidered, the ALS group showed associations between mean latency and mean latency standard
deviation of the ACCT subtests and frontal-executive measures (d2, MCST, RCPM, IGT),
together with RME as a measure of social cognition (Table 3 and S2 Table). Response accuracy
of the ACCT-2 subtest correlated with RME (number of correct responses) (S2 Table). For
controls, correlations were less extended and mainly regarded mean latency and mean latency
standard deviation of ACCT-2 and ACCT-3 subtests that correlated with frontal-executive
measures and control task at the RME (Table 3 and S3 Table). In this group, response accuracy
for the ACCT-1 subtest correlated with d2, MCST and RCPM measures; some trends were
Table 1. Performance on ACCT subtests in ALS patients and healthy subjects. Data are expressed as Means (SD).
ALS patients
N = 21
Healthy controls
N = 21
Mean (SD) Mean (SD) W/Z p-value
ACCT-1 mean latency 3.804 (0.798) 3.253 (0.452) 317 .015
ACCT-2 mean latency 4.288 (0.970) 3.647 (0.657) 312 .021
ACCT-3 mean latency 4.356 (0.826) 3.976 (0.770) 287 .1
ACCT-4 mean latency 4.282 (1.088) 3.503 (0.650) 318 .014
ACCT-1 sd latency 1.215 (1.680) 0.538 (0.403) 311 .023
ACCT-2 sd latency 1.204 (0.790) 0.798 (0.568) 292 .07
ACCT-3 sd latency 1.167 (0.534) 0.855 (0.366) 293 .07
ACCT-4 sd latency 1.617 (1.156) 0.855 (0.523) 313 .020
ACCT-1 n° correct 11.81 (0.51) 11.90 (0.30) -0.515 .7
ACCT-2 n° correct 10.86 (2.65) 11.71 (0.46) -1.417 .2
ACCT-3 n° correct 10.62 (2.50) 11.57 (0.81) -1.685 .1
ACCT-4 n° correct 10.71 (2.72) 11.57 (1.08) -1.838 .07
Bold numbers indicate statistical significance with p< 0.05.
Abbreviations: W = Wilcoxon; Z = exact Wilcoxon Mann-Whitney test; sd latency = mean latency standard
deviation; n˚ correct = number of correct responses.
https://doi.org/10.1371/journal.pone.0200953.t001
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also observed between response accuracy for the ACCT-3 subtest and the RCPM and RME
control task (S3 Table).
ACCT results: Correlation with clinical and psychological parameters
No significant correlations were observed between ACCT variables (mean latency and number
of correct responses), and either the disease onset or ALSFRS/R in the ALS patients’ group.
With regard to psychological components in the patients’ group, a negative correlation was
observed between state anxiety level (STAI-Y1) and mean latency standard deviation for the
ACCT-2 (rho = -.47; p-value = .031) and ACCT-3 (rho = -.59; p-value = .006) subtasks. Trait
anxiety (STAI-Y2) was positively correlated in this sample with number of correct responses at
the ACCT-3 subtask (rho = .45; p-value = .043).
The trait anxiety (STAI-Y2) for the control group was positively correlated with mean
latency at both ACCT-1 (rho = .52; p-value. = .016), ACCT-2 (rho = .52; p-value = .016) and
ACCT-3 (rho = .46; p-value = .035) subtests. Moreover, the level of depression (BDI) was posi-
tively correlated with the mean latency for ACCT-1 (BDI-SP: rho = .44; p-value = .043) and
ACCT-2 subtests (BDI-TOT tot: rho = .53; p-value = .013; BDI-CA: rho = .43; p-value = .05;
BDI-SP: rho = .60; p-value = .004), and with the mean latency standard deviation for ACCT-2
(BDI-TOT: rho = .46; p-value = .036; BDI-CA: rho = .50; p-value = .022).
No significant correlations were observed between ACCT subtest variables (mean latency,
mean latency standard deviation and number of correct responses) and patients’ behavioral
examination (FBI).
Fig 2. Errors distribution at the ACCT subtests in ALS patients. Err-A = partial errors following the ‘colour’ rule; Err-B = partial errors following the
‘direction’ rule; Err-P = perseverative errors.
https://doi.org/10.1371/journal.pone.0200953.g002
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Discussion
The ACCT we presented, highlighted the decreased performances of time-related measures of
ALS patients, when compared to controls. Less consistent results were observed with accu-
racy-related measures, i.e. number of correct responses, with a trend towards a significant dif-
ference observed across trials, from ACCT-1 to ACCT-4. ACCT-3 seems slightly more
difficult than the other subtests, according to the observed mean values and the lack of differ-
ences between patients and controls performances. Maybe, the increase of arrows numerosity
from ACCT-2 to ACCT-3 and the progressive instructions alternation involve a more signifi-
cant working memory load, as also suggested by the appearance of perseverative errors.
Overall, our findings suggest the presence of slight cognitive changes concerning cognitive
flexibility and set-shifting abilities in our non-demented ALS sample that may overtly affect
execution times and, to a lesser extent, performance accuracy. Recent findings have
highlighted functional reorganization in ALS patients during cognitive tasks as an early adap-
tive process to neuronal cell loss and time-related aspects could represent the initial clinical
signs of cognitive change in our ALS population [39]. Longitudinal evaluation of patients’ per-
formances using the ACCT test and other cognitive tasks could identify changes in perfor-
mances across disease progression and better characterize cognitive changes. Furthermore, it
is worth noting the few patients with ALSci in our sample (12.5%). Our small sample size
could explain the limited presence of cognitive involvement detected by the ACCT.
Table 2. Correlations between ACCT subtests and standard tests in patients and controls.
ALS patients Healthy controls
MoCA WM FAB MoCA WM FAB
ACCT-1 mean latency
(p-value)
-.48
(.05)
-.43
(.2)
-.06
(.8)
-.34
(.1)
.02
(.9)
-.24
(.3)
ACCT-2 mean latency
(p-value)
-.34
(.2)
-.44
(.2)
-.05
(.8)
-.38
(.09)
-.49
(.06)
-.03
(.9)
ACCT-3 mean latency
(p-value)
-.05
(.9)
-.42
(.2)
-.08
(.7)
-.42
(.06)
-.35
(.2)
.12
(.6)
ACCT-4 mean latency
(p-value)
-.11
(.7)
-.43
(.2)
-.10
(.7)
.06
(.8)
.17
(.5)
-.21
(.4)
ACCT-1 sd latency
(p-value)
-.27
(.3)
-.15
(.6)
.16
(.5)
-.33
(.1)
-.14
(.6)
-.16
(.5)
ACCT-2 sd latency
(p-value)
-.24
(.4)
-.60
(.038)
.13
(.6)
-.28
(.2)
-.59
(.020)
.00
(>.9)
ACCT-3 sd latency
(p-value)
-.28
(.3)
-.55
(.06)
.05
(.8)
-.27
(.2)
-.28
(.3)
.04
(.9)
ACCT-4 sd latency
(p-value)
-.32
(.2)
-.29
(.4)
-.27
(.3)
.03
(>.9)
.01
(>.9)
-.27
(.2)
ACCT-1 n° correct
(p-value)
.49
(.044)
-.32
(.3)
.06
(.8)
.29
(.2)
.39
(.2)
-.12
(.6)
ACCT-2 n° correct
(p-value)
.33
(.2)
.56
(.06)
.08
(.8)
-.26
(.3)
-.19
(.5)
.19
(.4)
ACCT-3 n° correct
(p-value)
.13
(.6)
.22
(.5)
-.53
(.025)
.49
(.023)
.35
(.2)
-.17
(.5)
ACCT-4 n° correct
(p-value)
.30
(.2)
.00
(>.9)
.08
(.7)
.10
(.7)
-.11
(.7)
-.00
(>.9)
Bold numbers indicate statistical significance with p< 0.05.
Abbreviations: MoCA = Montreal Cognitive Assessment; WM = Working Memory subtest; FAB = Frontal Assessment Battery; sd latency = mean latency standard
deviation; n˚ correct = number of correct responses.
https://doi.org/10.1371/journal.pone.0200953.t002
Oculomotor-based executive assessment in ALS
PLOS ONE | https://doi.org/10.1371/journal.pone.0200953 August 9, 2018 9 / 15
In contrast with our results, in a recent study, Pettit and colleagues concluded that process-
ing speed, when isolated from motor functions and high-order cognitive processes, is pre-
served in ALS patients, and, therefore, does not contribute to the frequently observed
cognitive changes in such a population [9]. A possible explanation of these controversial find-
ings could be that, in our study, the use of an oculomotor-driven version of the cognitive tests
could affect performance speed, due to the possible presence of ocular motor disorders as a
marker of sub-clinical frontal lobe dysfunction observed in ALS patients [40–42]. However,
the clinical examination that preceded the administration of the experimental protocol
excluded the presence of significant oculomotor dysfunctions. Moreover, the employed para-
digm minimized the oculomotor component necessary to provide responses to the presented
items. Finally, no correlation between patients’ physical function decline (ALSFRS/R) and
mean latency at the ACCT subtests was observed. Similarly, disease onset did not correlate
with time-related variables provided by the ACCT test. Overall, such results suggest that
motor limitation severity and progression did not influence the speed of processing in our
sample, and that such time-related aspects are likely related to an underlying cognitive
involvement.
Table 3. Correlations between ACCT subtests and other ET-based tests in patients and controls.
ALS patients Healthy controls
ACCT-1
Mean latency
ACCT-2
Mean latency
ACCT-3
Meanlatency
ACCT-4
Mean latency
ACCT-1
Mean latency
ACCT-2
Mean latency
ACCT-3
Mean latency
ACCT-4Mean latency
d2 mean latency
(p-value)
.73
(< .001)
.68
(.002)
.45
(.06)
.49
(.033)
.40
(.07)
.18
(.4)
.50
(.020)
.08
(.7)
d2 n° correct
(p-value)
-.46
(.046)
-.28
(.3)
-.46
(.045)
-.14
(.6)
-.18
(.4)
-.33
(.1)
-.28
(.2)
-.17
(.5)
MCST mean latency
(p-value)
.55
(.017)
.32
(.2)
.46
(.048)
.46
(.046)
.35
(.1)
.15
(.5)
.56
(.009)
.07
(.8)
MCST n° correct
(p-value)
-.19
(.4)
-.27
(.3)
-.42
(.08)
-.47
(.044)
-.31
(.2)
-.003
(>.9)
-.43
(.050)
-.08
(.7)
MCST n° categories
(p-value)
-.16
(.5)
-.37
(.1)
-.44
(.053)
-.40
(.08)
-.32
(.2)
.002
(>.9)
-.43
(.050)
-.08
(.7)
MCST n° cards
(p-value)
.19
(.4)
.37
(.1)
.47
(.038)
.47
(.037)
.30
(.2)
.003
(>.9)
38
(.09)
-.15
(.5)
RCPM mean latency
(p-value)
.44
.06)
.40
.09)
.57
.010)
.48
.037)
.26
.3)
.42
.06)
.74
< .001)
.35
.1)
RCPM n° correct
(p-value)
-.53
(.018)
-.26
(.3)
-.25
(.3)
-.49
(.034)
-.27
(.2)
-.53
(.012)
-.39
(.08)
-.15
(.5)
RME mean latency
(p-value)
.28
.2)
.12
.6)
.49
.036)
-.05
.9)
.04
.9)
.26
.3)
.18
.4)
.16
.5)
RME n° correct
(p-value)
-.31
(.2)
-.18
(.5)
.06
(.8)
-.20
(.4)
-.42
(.06)
-.23
(.3)
-.10
(.7)
.14
(.6)
RMEc mean latency
(p-value)
.84
(< .001)
.62
(.005)
.47
(.043)
.43
(.07)
.38
(.09)
.53
(.015)
.56
(.009)
.22
(.3)
RMEc n° correct
(p-value)
-.39
(.1)
-.24
(.3)
-.21
(.4)
-.27
(.3)
-.13
(.6)
-.24
(.3)
-.23
(.3)
.07
(.8)
IGT mean latency
(p-value)
.67
(.002)
.57
(.012)
.72
(< .001)
.62
(.006)
.21
(.4)
.42
(.06)
.36
(.1)
.33
(.1)
Bold numbers indicate statistical significance with p< 0.05.
Abbreviations: n˚ correct = number of correct responses; n˚ categories = number of achieved categories; n˚ cards = number of used cards; RMEc = Reading the Mind in
the eyes test–control test.
https://doi.org/10.1371/journal.pone.0200953.t003
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Correlations between ACCT and other ET-based measures of frontal-executive abilities
were extended and congruent, and mainly involved the mean latency variables of ACCT.
Some relationships have also been observed between ACCT and a measure of social cognition,
RME, suggesting a role for set-shifting and frontal-executive abilities in such function, as
reported previously [4].
Otherwise, ACCT demonstrated limited correlation with other standard cognitive tests,
such as the MoCA and a WM measure (Digit Sequencing Task), and very poor correlation
with a widely used battery that assesses frontal abilities (FAB). Discrepancy between the FAB
and ACCT tests could be explained by the poor sensitivity of the ‘paper and pencil’ frontal bat-
tery in non-demented ALS patients, as suggested by recent literature [43] and confirmed by
our study. Moreover, it is also likely that FAB and ACCT assessments target different compo-
nents of executive function. With regard to WM subtest, although several studies have pro-
posed a relationship between frontal-executive and WM abilities [44–46] and mild
dysfunction of WM abilities are consistent with previous, multidimensional reports [5, 47], we
observed limited correlation in our study between ACCT performances and WM subtests.
Further refinements of the developed test, aimed at increasing the level of difficulty and the
sensitivity of the different subtests, as well as comparison with other WM assessment tools,
could provide more consistent data.
In addition to time and accuracy-related variables, the developed ACCT test allows the col-
lection of more qualitative data about frontal-executive involvement than other available tests,
according to the categorization of errors presented. The preliminary findings presented here
suggest a reduced presence of perseverative errors, with respect to other type of errors, in our
sample of non-demented ALS patients. Such results are in accordance with a previous study
using a similar population where impaired inhibition was not a prominent feature [10]. More-
over, the use of a sophisticated and computerized tool, such as ET, could enable the collection
of findings that would provide insight into the nature of errors that patients make when scan-
ning items (i.e. perseverative, due to impulsivity or disinhibition). Further refinements of this
protocol, including detection of oculomotor performances, and recruiting patients with more
heterogeneous and severe cognitive impairments, could improve the test sensitivity and pro-
vide more subtle indications about cognitive performances.
Conclusions
In ALS, frontal abilities, and particularly cognitive flexibility, are known to be impaired due to
limitations in executive control in such patients. However, observations supporting such
changes have been often collected by means of tests that do not accommodate for verbal and
motor disabilities. The detection of cognitive impairments during the course of the disease is
not fully and reliably accomplished by means of ‘paper and pencil’ tests, because the motor
and verbal limitations are severe in moderate-severe stages of ALS. Such issues may at least
partially account for the inconsistency of findings obtained by previous studies about specific
components of cognitive involvement in the disease, including subcomponents of frontal-
executive abilities.
We presented preliminary results about an extensive neuropsychological battery developed
for oculo-motor control by means of ET, covering language, attentional and executive func-
tions, and social cognition domains. The current study provides clinical data of a newly devel-
oped measure, the Arrows and Colors Cognitive Test (ACCT), administered by means of ET
technology. The newly developed test allows a specific assessment of cognitive flexibility. Such
measures, when integrated to other complementary tasks, could provide a more specific evalu-
ation of different frontal changes involved in the course of ALS.
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Our results propose the use of ACCT as a tool to assess cognition in patients with verbal-
motor disabilities, such as ALS, when standard measures are not fully administrable. Further
efforts will be aimed at investigating the feasibility of the developed system, together with
validity and usability components, in larger populations of ALS patients. In particular, the
inclusion of ALS patients presenting overt cognitive or behavioral impairments, or FTD, will
be useful for improving ACCT clinical sensitivity. Finally, future research will be aimed at
enhancing the ACCT number of items and level of difficulty in order to improve both its sensi-
tivity and accuracy.
Despite these limitations, the findings reported in the present study represent the first con-
tribution towards the development of a full verbal-motor free executive test for ALS patients.
Accommodating or compensating for verbal-motor component is a crucial issue for longitudi-
nal assessment of cognition in ALS. Adequately assessing such cognitive components could
enhance clinical observations and better describe ALS patients’ phenotypes along the course of
the disease, avoiding biases present in clinical and research settings.
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